Article Text

Audit, research and guideline update
A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB
  1. J L Potter1,
  2. T Capstick2,
  3. W M Ricketts3,
  4. N Whitehead4,
  5. O M Kon5
  1. 1Department of Respiratory Medicine, Barts Health NHS Trust, London, UK
  2. 2Department of Medicines Management and Pharmacy Services, Leeds University Hospitals Trust, Leeds, UK
  3. 3Department of Respiratory Medicine, The Whittington Hospital, London, UK
  4. 4Department of Respiratory Medicine, Queen Alexandra Hospital, Portsmouth, UK
  5. 5Imperial College London, Chest and Allergy Clinic, London, UK
  1. Correspondence to Dr Jessica Louise Potter, Department of Respiratory Medicine, London Chest Hospital, Bonner Road, London E2 9JX, UK; Jessica.keal{at}gmail.com, Jessica.potter{at}bartshealth.nhs.uk

Abstract

Using the best available evidence and expert consensus, this document provides guidance for adverse effect monitoring in multidrug-resistant TB (MDR-TB). It includes recommendations for baseline tests, routine drug and toxicity monitoring guides as well as individual drug monographs for all drugs currently available in the UK to treat TB. These recommendations provide a structure through which healthcare professionals can better manage the complex drug regimens required for the treatment of MDR-TB; minimising the risk of adverse incidents and helping to improve patients’ tolerance, compliance and treatment completion.

  • Tuberculosis
  • Respiratory Infection
  • Drug reactions

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Statistics from Altmetric.com

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Airwaves
    Andrew Bush Ian Pavord